Search

Displaying results 8341 - 8350 of 9347 in total
  1. Drug

    Bexmarilimab

    go.drugbank.com/drugs/DB16383
    Investigational

    Bexmarilimab is under investigation in clinical trial NCT03733990 (A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients).

  2. Drug

    Lactoferrin

    go.drugbank.com/drugs/DB16555
    Investigational

    Lactoferrin is under investigation in clinical trial NCT03748043 (The Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis).

  3. Drug

    Azafenidin

    go.drugbank.com/drugs/DB19031
    Investigational

    Azafenidin is under investigation in clinical trial NCT01726582 (Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")).

  4. Drug

    CAR BCMA-CS1

    go.drugbank.com/drugs/DB17313
    Experimental

    CAR BCMA-CS1 is a lentiviral transfected chimeric antigen receptor (CAR) T-cell therapy modified to target B-cell maturation antigen and CS1.

    Synonyms: BCMA-CS1 cCAR T cell therapy
  5. Drug

    NY-ESO-1 peptide vaccine

    go.drugbank.com/drugs/DB17498
    Investigational

    It contains a peptide derived from the cancer-testis antigen (NY-ESO-1).

  6. Drug

    Ethaselen

    go.drugbank.com/drugs/DB15051
    Investigational

    Ethaselen is under investigation in clinical trial NCT02166242 (Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers).

  7. Drug

    ZEN-3694

    go.drugbank.com/drugs/DB22031
    Investigational

    ZEN-3694 is under investigation in clinical trial NCT04840589 (Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors).

  8. Drug

    D-Tyrosine

    go.drugbank.com/drugs/DB03839
    Experimental

    It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.

  9. Drug

    Senicapoc

    go.drugbank.com/drugs/DB06280
    Investigational

    [A259068] It is being investigated for the treatment of sickle cell disease.

  10. Drug

    SPL23-2

    go.drugbank.com/drugs/DB17866
    Experimental

    SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.[L46767]